drugset
Drugs / Sodium oligo-mannurarate
last change Jul 2023 re-read 3 minutes ago

Sodium oligo-mannurarate

also known as GV-971 · sodium oligomannate

Oligonucleotide (other)

Developed for
Alzheimer disease
Investigated by
Shanghai Greenvalley Pharmaceutical Co., Ltd. · Shanghai Mental Health Center

Trials 2

today NCT02293915 · Ph 3 NCT01453569 · Ph 2
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial · 1 missed
Phase 2 NCT01453569 Oct 2011 → Aug 2013 Alzheimer disease Shanghai Greenvalley Pharmaceutical Co., Ltd. Completed Missed primary
Phase 31 trial · 1 met primary
Phase 3 NCT02293915 Apr 2014 → Jun 2018 Alzheimer disease Shanghai Greenvalley Pharmaceutical Co., Ltd. Completed Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2023-07-31 Shanghai Greenvalley Pharmaceutical Co., Ltd. 甘露特钠胶囊(GV-971)改善阿尔茨海默病认知障碍并降低神经炎症的机制研究 greenvalleypharma.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Sodium oligo-mannurarate ClinicalTrials.gov intervention name — accepted as the source's own label NCT01453569 ↗
1

NCT02293915 ↗
Known as GV-971 “Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.” PMID 32928279 ↗ Sep 2020
Known as sodium oligomannate “Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.” PMID 32928279 ↗ Sep 2020
Modality Oligonucleotide (other) “Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.” PMID 32928279 ↗ Sep 2020
Route Oral “sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks” NCT01453569 ↗